Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Vapendavir Tablet vs Capsule in Healthy Volunteers
NCT02101866Phase 1Completed
- Sponsor
- Aviragen Therapeutics
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Vapendavir in rhinovirus infection (2 arms), sponsored by Aviragen Therapeutics. Primary endpoint: Systemic exposure profile of a single dose of vapendavir up to 46 days. Started Mar 2014; status: completed.
02
Drugs
Vapendavir
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT02101866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101866.